BS_R13X6TMW
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 25.755584756898816
- age_years
- 0.575
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.538
- CHOLESTEROL_HOMEOSTASIS+0.408
- FATTY_ACID_METABOLISM+0.397
- INTERFERON_ALPHA_RESPONSE+0.383
- DNA_REPAIR+0.382
- MYC_TARGETS_V1+0.357
- ANGIOGENESIS+0.350
- COAGULATION+0.328
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.328
- ADIPOGENESIS+0.309
Top 10 suppressed
- G2M_CHECKPOINT-0.440
- MITOTIC_SPINDLE-0.413
- UV_RESPONSE_DN-0.363
- E2F_TARGETS-0.296
- APICAL_SURFACE-0.284
- ESTROGEN_RESPONSE_EARLY-0.280
- WNT_BETA_CATENIN_SIGNALING-0.238
- PI3K_AKT_MTOR_SIGNALING-0.170
- SPERMATOGENESIS-0.159
- NOTCH_SIGNALING-0.158
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-49-4488-01A-01R-1755-07 | — | cohortA1 | 0.813 |
| 2 | SRR8752372 | — | — | 0.803 |
| 3 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.802 |
| 4 | 10013d81-e167-4aa0-b548-5bb359ed403a | — | — | 0.798 |
| 5 | AUR-AER6-TTM7-A-1-1-R-A742-41 | — | C | 0.784 |
| 6 | 31550B35-DA39-4294-8368-811A412B2E3A | — | — | 0.779 |
| 7 | TCGA-38-4632-01A-01R-1755-07 | — | cohortA1 | 0.773 |
| 8 | TCGA-05-4418-01A-01R-1206-07 | — | cohortA4 | 0.773 |
| 9 | MNG520 | — | — | 0.773 |
| 10 | TCGA-49-4494-01A-01R-1206-07 | — | cohortA1 | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.538 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.408 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.397 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.383 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.382 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.357 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| COAGULATION | 0.328 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.328 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.309 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.305 | Idelalisib | — uncovered |
| COMPLEMENT | 0.279 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.278 | Inavolisib | — uncovered |
| PEROXISOME | 0.266 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.264 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.201 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.201 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.193 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.193 | Inavolisib | — uncovered |